AGIO实时信号 | 通过Getagraph.com最大化利润

购买 107824 min ago

@ $25.84

发出时间: 15 Feb 2024 @ 02:56

回报率: 27.01%

上一信号: Feb 14 - 22:30

上一信号: 出售

回报率: 1.31 %

Live Chart Being Loaded With Signals

Commentary (30 Apr 2024 @ 00:00):

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology...

Stats
今日成交量	325 903
平均成交量	753 064
市值	1.82B
EPS	$-1.720 ( 2024-02-21 )
下一个收益日期	( $-1.640 ) 2024-05-02
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-8.37
ATR14	$0.0500 (0.15%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-08	Fouse Jacqualyn A	Buy	15 934	Common stock
2024-04-10	Fouse Jacqualyn A	Sell	7 791	Common stock
2024-04-08	Fouse Jacqualyn A	Sell	15 934	Restricted stock units
2024-03-07	Foster-cheek Kaye I	Sell	1 285	Common stock
2024-03-05	Foster-cheek Kaye I	Sell	300	Common stock

INSIDER POWER
24.99
Last 100 transactions
Buy: 882 792 \| Sell: 538 174

音量相关性

長: 0.05 (neutral)

短: -0.27 (neutral)

Signal:(42.673) Neutral

Agios Pharmaceuticals Inc 相关性

10 最正相关
NEOG	0.95
LSXMA	0.941
EAR	0.94
VORB	0.94
LSXMK	0.94
STAF	0.938
VERU	0.936
TTOO	0.936
OCC	0.935
ACCD	0.935

10 最负相关
EBSB	-0.952
PAE	-0.944
RMRM	-0.935
THRN	-0.933
SERA	-0.925
CYT	-0.924
BWC	-0.921
ZGNX	-0.919
MLTX	-0.919
GXII	-0.918

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Agios Pharmaceuticals Inc 相关性 - 货币/商品

-0.18
( neutral )

-0.09
( neutral )

0.00
( neutral )

-0.10
( neutral )

-0.69
( moderate negative )

-0.31
( neutral )

Agios Pharmaceuticals Inc 财务报表

Annual	2023
营收:	$26.82M
毛利润:	$17.32M (64.57 %)
EPS:	$-6.33

FY	2023
营收:	$26.82M
毛利润:	$17.32M (64.57 %)
EPS:	$-6.33

FY	2022
营收:	$14.24M
毛利润:	$12.54M (88.03 %)
EPS:	$-1.360

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$26.55

Financial Reports:

No articles found.

Agios Pharmaceuticals Inc

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

实时更新： Agios Pharmaceuticals Inc [AGIO]

Upcoming Earnings Alert